A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

NCT07250646 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary AML
Myelofibrosis

Interventions

DRUG: rebecsinib

Sponsor

Aspera Biomedicines, Inc.

Collaborators

[object Object]